Compliment factor i bioassay
AssigneeGlaxosmithkline Intellectual Property (No.2) Limited
InventorFrancisco LOPEZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to a CFI bioactivity assay designed to quantitatively measure (a) CFI bioactivity of plasma or other body fluids; and (b) bioactivity of CFI in plasma or other body fluids of a human patient afflicted by a disease that involves amyloid deposition in tissues, in particular Alzheimer disease, AMD, glaucoma, or beta-amyloid cataract formation.
Claims6
A method of quantitatively measuring the CFI bioactivity of a human body fluid or the bioactivity of complement factor I (CFI) in a human body fluid comprising the steps of measuring the ability of body fluid or CFI to convert C3b to iC3b.
A method of quantitatively measuring the CFI bioactivity of a human body fluid or the bioactivity of CFI in a human body fluid comprising the steps of
- (a) diluting the human body fluid with a diluent;
- (b) adding complement factor H (CFH) and C3b to the diluted human fluid;
- (c) incubating the resultant solution of step (b);
- and
- (d) measuring the amount of iC3b generated.
Dependencies are inferred from the claim text.